Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6121051 | 1.00 | PYGL (0.35) | PYGLCYP2C9ALDH1A1SLC1A3SLC1A2 | |
| SCHEMBL903751 | 1.00 | PYGL (0.35) | PYGLCYP2C9ALDH1A1SLC1A3SLC1A2 | |
| SCHEMBL241112 | 1.00 | PYGL (0.35) | PYGLCYP2C9ALDH1A1SLC1A3SLC1A2 | |
| SCHEMBL901563 | 1.00 | PYGL (0.35) | PYGLCYP2C9ALDH1A1SLC1A3SLC1A2 | |
| SCHEMBL193140 | 1.00 | PYGL (0.35) | PYGLCYP2C9ALDH1A1SLC1A3SLC1A2 | |
| SCHEMBL12557071 | 0.86 | HTT (0.38) | PYGLCYP2C9ALDH1A1SMN1; SMN2 | |
| SCHEMBL17327099 | 0.83 | — | — | |
| SCHEMBL5146050 | 0.83 | CTSK (0.49) | CTSSCTSK | |
| SCHEMBL10660662 | 0.83 | SMN1; SMN2 (0.38) | PYGLCYP2C9ALDH1A1SMN1; SMN2TYR | |
| SCHEMBL10398797 | 0.83 | SMN1; SMN2 (0.38) | PYGLCYP2C9ALDH1A1SMN1; SMN2TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108349907-B | 1,4(1,4) -diphenylheterocycle hexa-tomato-12,43-diyl derivatives, process for their preparation and their use | 江苏豪森药业集团有限公司 | 2021-08-31 | — | — | CN | disclosed |
| WO-2021080458-A1 | PANGENOTYPIC INHIBITOR OF HEPATITIS C VIRUS NS5A PROTEIN | ИВАЩЕНКО, Александр Васильевич | 2021-04-29 | — | — | WO | disclosed |
| CN-112638368-A | Process for the manufacture of piretavir active pharmaceutical substance | 艾伯维公司 | 2021-04-09 | — | — | CN | disclosed |
| EP-3699176-A2 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2020-04-23 | — | — | US | disclosed |
| US-20190337960-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2019-11-07 | — | — | US | disclosed |
| US-10344019-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2019-07-09 | — | — | US | disclosed |
| EP-3284741-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-2640719-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9156823-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2850085-A1 | ANTIVIRAL COMPOUNDS INHIBITORS OF HCV NS5B | Gilead Pharmasset LLC (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | Gelead Sciences, Inc. | 2014-01-16 | — | — | US | disclosed |
| WO-2013173488-A1 | ANTIVIRAL COMPOUNDS INHIBITORS OF HCV NS5B | GILEAD SCIENCES, INC. (US) | 2013-11-21 | — | — | WO | disclosed |
| EP-2640719-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| EP-2621931-A1 | TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | Merck Sharp & Dohme Corp. (US) | 2013-08-07 | — | — | EP | disclosed |
| CN-102741241-A | Benzimidazole-imidazole derivatives | TIBOTEC PHARM LTD | 2012-10-17 | — | — | CN | disclosed |
| WO-2012068234-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012041014-A1 | TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | PYGL 2026/4885CYP2C9 3296/4885ALDH1A1 3957/4885 |
| US-10344019-B2 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | PYGL 2026/4885CYP2C9 3296/4885ALDH1A1 3957/4885 |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | PYGL 2026/4885CYP2C9 3296/4885ALDH1A1 3957/4885 |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | PYGL 2026/4885CYP2C9 3296/4885ALDH1A1 3957/4885 |
| US-20190337960-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PYGL 844/4885CYP2C9 3743/4885ALDH1A1 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.